Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab ; volume:22 ; number:1 ; day:5 ; month:11 ; year:2022 ; pages:1-5 ; date:12.2022
BMC urology ; 22, Heft 1 (5.11.2022), 1-5, 12.2022
- Urheber
-
Kamitani, Rei
Ando, Toshiyuki
Hanai, Kazuya
Tanaka, Arihito
Kashizaki, Fumihiro
Sekido, Yasutomo
Mizuno, Ryuichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-022-01130-4
- URN
-
urn:nbn:de:101:1-2023012021594103645371
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kamitani, Rei
- Ando, Toshiyuki
- Hanai, Kazuya
- Tanaka, Arihito
- Kashizaki, Fumihiro
- Sekido, Yasutomo
- Mizuno, Ryuichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation
Molecular mechanisms of etoposide
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation
Molecular mechanisms of etoposide
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation